These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12464661)

  • 1. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 3. [Protein repair therapy in cystic fibrosis].
    Clément A; Tamalet A; Fauroux B; Epaud R
    Rev Prat; 2003 Jan; 53(2):163-6. PubMed ID: 12664848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pharmacologic therapies for cystic fibrosis.
    Zeitlin PL
    J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
    Kerem E
    Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty years after cystic fibrosis gene identification: Where are we and what are we up to?
    Edelman A; Fritsch J; Ollero M
    Pathol Biol (Paris); 2011 Jun; 59(3):131-3. PubMed ID: 19896304
    [No Abstract]   [Full Text] [Related]  

  • 8. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
    Kim Chiaw P; Eckford PD; Bear CE
    Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new frameshift mutation 460delG in exon 4 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
    Wagner K; Schneditz P; Rosenkranz W
    Hum Mutat; 1996; 7(2):183. PubMed ID: 8829644
    [No Abstract]   [Full Text] [Related]  

  • 10. [CFTR protein and molecular mechanisms of pulmonary involvement in cystic fibrosis].
    Chinet T
    Rev Pneumol Clin; 1995; 51(3):122-9. PubMed ID: 7569573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis.
    Derichs N; Schuster A; Grund I; Ernsting A; Stolpe C; Körtge-Jung S; Gallati S; Stuhrmann M; Kozlowski P; Ballmann M
    Clin Genet; 2005 Jun; 67(6):529-31. PubMed ID: 15857421
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacologic approaches to correcting the basic defect in cystic fibrosis.
    Lukacs GL; Durie PR
    N Engl J Med; 2003 Oct; 349(15):1401-4. PubMed ID: 14534332
    [No Abstract]   [Full Text] [Related]  

  • 13. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel nonsense mutation, S466Xa in exon 10 of the cystic fibrosis transmembrane conductance regulator gene.
    Mittre H; Barre M; Leymarie P
    Hum Mutat; 1996; 8(4):392-3. PubMed ID: 8956053
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cystic fibrosis: the CFTR gene, its mutations, the genetic counseling].
    Goossens M; Ghanem N; Girodon E; Costes B; Fanen P
    Rev Pneumol Clin; 1995; 51(3):130-6. PubMed ID: 7569574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells.
    Singh OV; Vij N; Mogayzel PJ; Jozwik C; Pollard HB; Zeitlin PL
    J Proteome Res; 2006 Mar; 5(3):562-71. PubMed ID: 16512671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis.
    Rowe SM; Miller S; Sorscher EJ
    N Engl J Med; 2005 May; 352(19):1992-2001. PubMed ID: 15888700
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction to section III: biochemical methods to study CFTR protein.
    Amaral MD; Lukacs GL
    Methods Mol Biol; 2011; 741():213-8. PubMed ID: 21594787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.
    Cormet-Boyaka E; Jablonsky M; Naren AP; Jackson PL; Muccio DD; Kirk KL
    Proc Natl Acad Sci U S A; 2004 May; 101(21):8221-6. PubMed ID: 15141088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.